Compare LEA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEA | IBRX |
|---|---|---|
| Founded | 1917 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.2B |
| IPO Year | 1994 | 2015 |
| Metric | LEA | IBRX |
|---|---|---|
| Price | $135.66 | $8.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $132.21 | $12.57 |
| AVG Volume (30 Days) | 677.0K | ★ 11.3M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $23,259,100,000.00 | $113,288,000.00 |
| Revenue This Year | $2.50 | $88.59 |
| Revenue Next Year | $3.12 | $131.15 |
| P/E Ratio | $41.38 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $91.67 | $1.95 |
| 52 Week High | $150.33 | $12.43 |
| Indicator | LEA | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 66.08 |
| Support Level | $115.63 | $6.69 |
| Resistance Level | $141.92 | $9.54 |
| Average True Range (ATR) | 4.06 | 0.50 |
| MACD | -1.29 | 0.15 |
| Stochastic Oscillator | 9.91 | 86.56 |
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.